February 17, 2026
One of the latest health crazes to slip in alongside “peptides” (see our previous series), is the idea that powerful medicines can be repurposed as lifestyle tweaks by “microdosing”: a tiny dose of a diabetes drug to “optimize” metabolism, a fraction of a psychedelic to sharpen focus, or a whisper of a stimulant to fuel a long workday. Microdosing has become a cultural shorthand for “safer and subtler” experimentation with powerful drugs with an exciting subtext: if a lot can be transformative, surely a little must be beneficial.
The idea of microdosing is far older than the Instagram‑friendly regimens of today. People have long used psychedelics such as LSD, ayahuasca, DMT, and psilocybin for creativity, insight, and scientific discovery. At roughly 5-10% of a full dose, microdosing started as an experimental regimen with these psychedelics and was first popularized by Albert Hofmann in the 1970s. Then in 2011, psychologist James Fadiman’s book, The Psychedelic Explorer’s Guide, sparked renewed interest and helped push the concept into mainstream conversation.
Dr Fadiman went on to collect data from over 1700 individuals who microdosed LSD and published a paper on their subjective experiences, suggesting that microdosing may support focus in a manner similar to the effects of ADHD stimulants like Ritalin. Benefits most commonly reported from microdosed psychedelics include improved mood, improved focus and increased creativity [1, 2]. Some individuals even suggested that microdosing helped with other health problems such as migraine, shingles and PMS.
But retrospective self‑reports are highly subjective and lack scientific rigor; they don’t tell us whether a drug actually works to treat a condition. Importantly, expectations underpin the placebo effect, and expecting a particular outcome has been demonstrated to impact everything from pain medication to antidepressants [3, 4]. And when it comes to treating psychiatric disorders, there is little evidence to support microdosing. Only a handful of rigorous trials have been conducted, and while some report short‑lived shifts in mood, they do not support microdosing as an effective long‑term treatment strategy for mood disorders [5].
MindBio’s most recent trial data further underscore this efficacy gap. Despite posting improved depression scores from an 8-week Phase 2A microdosing trial on 19 participants (15 male, microdoses between 6 and 20ug of LSD) [6], a larger and more rigorous Phase 2B trial with 89 participants, reported that microdoses of LSD were no better than caffeine placebo in treating major depressive disorder. This is the same company that failed to show any benefit in microdosing LSD (20ug) for ADHD [7].
Why the discrepancy between two studies run by the same company? In the first trial, participants were not blinded to the treatment. In the second, the design was triple‑blinded and double‑placebo: participants were told they might receive LSD, Ritalin, or caffeine, and neither they nor the researchers knew which one they had until the trial ended. The fact that rigorous blinding erased the apparent benefits of microdosed LSD highlights just how potent placebo effects can be in mood‑disorder treatment.
Even so, expectations do not always produce the outcomes people anticipate. In 2022, a study assessed the experiences of over 6700 individuals who microdose LSD or psilocybin. The authors speculated that those with an “approach-motivation” ( a desire to focus on positive goals, rewards, and growth), would experience greater benefits than those with an “avoidance-motivation” (a desire to escape from worries or problems), however researchers found that those with approach-motivation actually resulted in less beneficial subjective experiences [2]. Around 42% of participants also reported that full doses were more beneficial than microdoses. Despite these findings, microdosing of psychedelics is experiencing a resurgence, and sites like the microdosing institute now offer resources on issues such as known drug and supplement interactions often drawing on crowd‑sourced data.
The idea of microdosing other non-psychedelic drugs has quietly slipped into the mainstream, helped along by GLP-1 drug shortages, the peptide craze, and a constant social media slipstream (TikTok, Instagram, reddit and X are all sources). The appeal rests on the assumption that a very small dose can produce a beneficial physiological (or psychological) effect without any of the typical adverse effects of a full dose. This logic is rarely true in pharmacology.
Crucially, microdosing is not the same as dose titration. In search of the pharmacological “Goldilocks Zone”, clinicians routinely adjust medication doses to account for individual biology, side‑effect burden, and comorbidities [8]. But tailoring a therapeutic dose within an evidence‑based range is very different from chronically taking a fraction of that dose based on vibes and anecdotes. “Personalized dosing” in a clinical context aims to reach a known effective window; microdosing, as it is often promoted, never gets there.
People are now microdosing GLP-1 receptor agonists semaglutide and tirzepatide (at 0.25mg), sometimes to reduce the overall cost, sometimes as a stepping-stone toward a full dose while avoiding the more onerous gastrointestinal side-effects. The latter can resemble legitimate titration. But others in the biohacking community are microdosing GLP-1 RAs for perceived “metabolic tuning”, “inflammation or pain reduction”, or “anti-aging” —benefits that have yet to be demonstrated with robust clinical evidence. Some wellness clinics even pair GLP-1 RAs with microdose injections of nicotinamide adenine dinucleotide (NAD+) and/or Vitamin B12, with sellers claiming everything from enhancing longevity to better sleep. But even at full doses, there are no robust human trials demonstrating efficacy for the purported benefits of injected NAD+, let alone at microdoses [9].
Reddit and Discord forums are now full of conversations about microdosing everything from anabolic steroids, to caffeine or nicotine. Some advocate “micro‑sipping” coffee or tea, or using low‑dose nicotine patches or vaping, to maintain alertness without jitteriness or big tolerance spikes. Despite one animal study showing that very low oral doses of nicotine (equivalent to ~1ug/day in humans) increased NAD+ synthesis in mice [10], no studies have replicated this in humans. In practice, dosing nicotine that low outside of a lab would be nearly impossible: a single 2mg piece of gum would have to be cut into 2000 pieces to match the human- equivalent dose.
The real story of microdosing isn’t about clever biohacks. It’s about the collision of pharmacology, eroding trust in institutions, and our relentless desire for control of our bodies, all amplified by individuals and companies eager to make money off the “biohacking” trend. It shows how easily a sophisticated pharmacological concept can be stripped of context and, then flattened into click-bait that promises “gentle but powerful” results. This is exactly where pseudoscience flourishes: a kernel of real pharmacology mixed with wishful thinking, turning ‘a little bit of knowledge’ into a marketing tool that feels scientific while quietly discarding the actual evidence.
In that light, the most ethical path forward is not to chase ever‑smaller doses, but to demand better evidence and to hold both companies and individuals accountable for the narratives they sell about “a little bit of good.”
References
[1] T. Anderson et al., “Psychedelic microdosing benefits and challenges: an empirical codebook.,” Harm Reduct. J., vol. 16, no. 1, p. 43, Jul. 2019, doi: 10.1186/s12954-019-0308-4.
[2] R. Petranker, T. Anderson, L. J. Maier, M. J. Barratt, J. A. Ferris, and A. R. Winstock, “Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.,” J. Psychopharmacol., vol. 36, no. 1, pp. 85–96, Jan. 2022, doi: 10.1177/0269881120953994.
[3] L. Holper, “Raising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis,” Front. Psychiatry, vol. Volume 11-2020, 2020, [Online]. Available: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2020.00633
[4] J. A. Turner, R. A. Deyo, J. D. Loeser, M. Von Korff, and W. E. Fordyce, “The importance of placebo effects in pain treatment and research.,” JAMA, vol. 271, no. 20, pp. 1609–1614, May 1994.
[5] R. J. Murphy, S. Muthukumaraswamy, and H. de Wit, “Microdosing Psychedelics: Current Evidence From Controlled Studies,” Biol. Psychiatry Cogn. Neurosci. Neuroimaging, vol. 9, no. 5, pp. 500–511, 2024, doi: https://doi.org/10.1016/j.bpsc.2024.01.002.
[6] D. Daldegan-Bueno et al., “LSD microdosing in major depressive disorder: results from an open-label trial,” Neuropharmacology, vol. 283, p. 110762, 2026, doi: https://doi.org/10.1016/j.neuropharm.2025.110762.
[7] L. Mueller et al., “Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.,” JAMA psychiatry, vol. 82, no. 6, pp. 555–562, Jun. 2025, doi: 10.1001/jamapsychiatry.2025.0044.
[8] R. W. Peck, M. H. Shahin, and A. A. Vinks, “Precision Dosing: The Clinical Pharmacology of Goldilocks,” Clin. Pharmacol. Ther., vol. 109, no. 1, pp. 11–14, Jan. 2021, doi: https://doi.org/10.1002/cpt.2112.
[9] I. de M. Gindri et al., “Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review,” Am. J. Physiol. Metab., vol. 326, no. 4, pp. E417–E427, Nov. 2023, doi: 10.1152/ajpendo.00242.2023.
[10] L. Yang et al., “Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity,” Nat. Commun., vol. 14, no. 1, p. 900, 2023, doi: 10.1038/s41467-023-36543-8.